Literature DB >> 23945382

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

Xin Ye1, Zhong-Zheng Zhu, Lei Zhong, Yachao Lu, Yun Sun, Xiaolu Yin, Zhenfan Yang, Guanshan Zhu, Qunsheng Ji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23945382     DOI： 10.1097/JTO.0b013e31829f691f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  29 in total

Review 1.  Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Adrian G Sacher; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer       Date:  2014-04-17       Impact factor: 6.860

2.  Non-reproducible sequence artifacts in FFPE tissue: an experience report.

Authors:  Richard Ofner; Cathrin Ritter; Selma Ugurel; Lorenzo Cerroni; Mathias Stiller; Thomas Bogenrieder; Flavio Solca; David Schrama; Jürgen C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-17       Impact factor: 4.553

3.  Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Authors:  Aaron N Hata; Harald Paganetti; Clemens Grassberger; David McClatchy; Changran Geng; Sophia C Kamran; Florian Fintelmann; Yosef E Maruvka; Zofia Piotrowska; Henning Willers; Lecia V Sequist
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

4.  The cellular origins of drug resistance in cancer.

Authors:  Geoffrey R Oxnard
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

5.  Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.

Authors:  Yuan Tang; Nanying Che; Yang Yu; Yun Gao; Huaiyin Shi; Qin Feng; Bing Wei; Liheng Ma; Min Gao; Jie Ma; Dongmei Lin
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-06       Impact factor: 4.553

6.  Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.

Authors:  Pham Nguyen Quy; Masashi Kanai; Keita Fukuyama; Tadayuki Kou; Tomohiro Kondo; Yoshihiro Yamamoto; Junichi Matsubara; Akinori Hiroshima; Hiroaki Mochizuki; Tomohiro Sakuma; Mayumi Kamada; Masahiko Nakatsui; Yuji Eso; Hiroshi Seno; Toshihiko Masui; Kyoichi Takaori; Sachiko Minamiguchi; Shigemi Matsumoto; Manabu Muto
Journal:  Oncologist       Date:  2019-06-11

7.  The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR.

Authors:  Tsutomu Tatematsu; Katsuhiro Okuda; Ayumi Suzuki; Risa Oda; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Hidefumi Sasaki; Ryoichi Nakanishi
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

8.  Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

Authors:  Jason J Luke; Geoffrey R Oxnard; Cloud P Paweletz; D Ross Camidge; John V Heymach; David B Solit; Bruce E Johnson
Journal:  J Natl Cancer Inst       Date:  2014-08-08       Impact factor: 13.506

9.  Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

Authors:  H A Yu; M E Arcila; M D Hellmann; M G Kris; M Ladanyi; G J Riely
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

10.  The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer.

Authors:  Najwa El Kadi; Luo Wang; April Davis; Hasan Korkaya; Alexander Cooke; Varun Vadnala; Noah A Brown; Bryan L Betz; Marilia Cascalho; Gregory P Kalemkerian; Khaled A Hassan
Journal:  Cancer Res       Date:  2018-10-17       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.